Meeting
2022 ASCO Annual Meeting
NSABP FC-10: A phase Ib study of pembrolizumab (pembro) in combination with pemetrexed (pem) and oxaliplatin (oxali) in patients with chemo-refractory metastatic colorectal cancer (mCRC).
Authors
John C. Krauss
University of Michigan, Ann Arbor, MI
John C. Krauss , Greg Yothers , Thomas J. George , James Lloyd Wade III, Atrayee Basu Mallick , James J. Lee , Shannon Leigh Huggins-Puhalla , Carmen Joseph Allegra , Samuel A. Jacobs , Norman Wolmark
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT03626922
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3569)
DOI
10.1200/JCO.2022.40.16_suppl.3569
Abstract #
3569
Poster Bd #
363
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Quadruplet regimen with capecitabine, irinotecan, oxaliplatin, and bevacizumab in chemo-naive patients with metastatic colorectal cancer: Results from the safety lead-in of QUATTRO-II study.
First Author: Hideaki Bando
Poster
2020 ASCO Virtual Scientific Program
Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial.
First Author: Georg Martin Haag
Poster
2020 Gastrointestinal Cancers Symposium
NSABP FC-10: Phase IB study of pembrolizumab in combination with premetrexed + oaliplatin in patients (pts) with chemo-refractory metastatic colorectal cancer (mCRC).
First Author: James J. Lee
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Trial in progress: A phase II study (with safety run-in) of evorpacept (ALX148), cetuximab, and pembrolizumab in patients with refractory microsatellite-stable metastatic colorectal cancer (AGICC-ALX148 21CRC01).
First Author: Robert William Lentz